SRNE logo

Sorrento Therapeutics (SRNE) Cash From Operations

Annual CFO

-$293.86 M
-$12.04 M-4.27%

December 31, 2022


Summary


Performance

SRNE Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherSRNEcash flowmetrics:

Quarterly CFO

-$55.66 M
-$6.20 M-12.54%

June 30, 2023


Summary


Performance

SRNE Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherSRNEcash flowmetrics:

TTM CFO

-$234.63 M
+$25.33 M+9.74%

June 30, 2023


Summary


Performance

SRNE TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherSRNEcash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

SRNE Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-4.3%-12.5%+9.7%
3 y3 years-69.9%-12.5%+9.7%
5 y5 years-196.3%-12.5%+9.7%

SRNE Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-4.3%at low-12.5%+33.2%at high+26.6%
5 y5-year-84.2%at low-54.5%+33.2%-51.7%+26.6%
alltimeall time<-9999.0%at low-4398.0%+33.2%<-9999.0%+26.6%

Sorrento Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Jun 2023
-
-$55.66 M(+12.5%)
-$234.63 M(-9.7%)
Mar 2023
-
-$49.46 M(-27.6%)
-$259.96 M(-11.5%)
Dec 2022
-$293.86 M(+4.3%)
-$68.34 M(+11.7%)
-$293.86 M(-1.3%)
Sep 2022
-
-$61.17 M(-24.5%)
-$297.66 M(-6.9%)
Jun 2022
-
-$80.99 M(-2.8%)
-$319.60 M(+0.8%)
Mar 2022
-
-$83.36 M(+15.6%)
-$317.12 M(+12.5%)
Dec 2021
-$281.82 M(+76.7%)
-$72.14 M(-13.2%)
-$281.82 M(+12.5%)
Sep 2021
-
-$83.11 M(+5.9%)
-$250.55 M(+19.3%)
Jun 2021
-
-$78.52 M(+63.4%)
-$210.03 M(+24.2%)
Mar 2021
-
-$48.06 M(+17.6%)
-$169.04 M(+6.0%)
Dec 2020
-$159.54 M(-7.8%)
-$40.87 M(-4.0%)
-$159.54 M(+3.1%)
Sep 2020
-
-$42.59 M(+13.5%)
-$154.69 M(-2.1%)
Jun 2020
-
-$37.52 M(-2.7%)
-$157.93 M(-5.6%)
Mar 2020
-
-$38.55 M(+7.0%)
-$167.24 M(-3.3%)
Dec 2019
-$173.00 M(+54.8%)
-$36.02 M(-21.4%)
-$173.00 M(-4.9%)
Sep 2019
-
-$45.83 M(-2.1%)
-$181.95 M(+16.0%)
Jun 2019
-
-$46.83 M(+5.7%)
-$156.82 M(+18.7%)
Mar 2019
-
-$44.31 M(-1.5%)
-$132.11 M(+18.2%)
Dec 2018
-$111.77 M(+12.7%)
-$44.98 M(+117.2%)
-$111.77 M(+0.1%)
Sep 2018
-
-$20.70 M(-6.4%)
-$111.64 M(+7.8%)
Jun 2018
-
-$22.12 M(-7.7%)
-$103.60 M(+2.3%)
Mar 2018
-
-$23.96 M(-46.6%)
-$101.23 M(+2.1%)
Dec 2017
-$99.18 M(+39.8%)
-$44.85 M(+254.2%)
-$99.18 M(+40.0%)
Sep 2017
-
-$12.66 M(-35.9%)
-$70.84 M(-11.7%)
Jun 2017
-
-$19.75 M(-9.9%)
-$80.23 M(+10.4%)
Mar 2017
-
-$21.91 M(+32.7%)
-$72.66 M(+2.4%)
Dec 2016
-$70.93 M(+68.6%)
-$16.52 M(-25.1%)
-$70.93 M(+0.5%)
Sep 2016
-
-$22.05 M(+81.1%)
-$70.57 M(+5.5%)
Jun 2016
-
-$12.18 M(-39.7%)
-$66.88 M(+25.2%)
Mar 2016
-
-$20.19 M(+24.9%)
-$53.41 M(+27.0%)
Dec 2015
-$42.07 M(+46.3%)
-$16.16 M(-11.9%)
-$42.07 M(+25.3%)
Sep 2015
-
-$18.36 M(-1517.4%)
-$33.56 M(+61.3%)
Jun 2015
-
$1.29 M(-114.6%)
-$20.80 M(-27.0%)
Mar 2015
-
-$8.85 M(+15.6%)
-$28.49 M(-1.0%)
Dec 2014
-$28.76 M(+74.4%)
-$7.66 M(+36.8%)
-$28.76 M(+1.6%)
Sep 2014
-
-$5.60 M(-12.4%)
-$28.32 M(+10.2%)
Jun 2014
-
-$6.39 M(-30.0%)
-$25.70 M(+11.1%)
Mar 2014
-
-$9.12 M(+26.5%)
-$23.13 M(+40.3%)
DateAnnualQuarterlyTTM
Dec 2013
-$16.49 M(+334.3%)
-$7.21 M(+141.9%)
-$16.49 M(+55.5%)
Sep 2013
-
-$2.98 M(-21.9%)
-$10.61 M(+23.0%)
Jun 2013
-
-$3.81 M(+53.7%)
-$8.63 M(+57.4%)
Mar 2013
-
-$2.48 M(+86.8%)
-$5.48 M(+44.4%)
Dec 2012
-$3.80 M(+38.4%)
-$1.33 M(+33.0%)
-$3.80 M(+26.3%)
Sep 2012
-
-$999.40 K(+48.9%)
-$3.01 M(+15.7%)
Jun 2012
-
-$671.30 K(-15.8%)
-$2.60 M(-16.5%)
Mar 2012
-
-$797.60 K(+48.0%)
-$3.11 M(+13.5%)
Dec 2011
-$2.74 M(+77.4%)
-$539.00 K(-8.7%)
-$2.74 M(+17.6%)
Sep 2011
-
-$590.40 K(-50.2%)
-$2.33 M(+19.3%)
Jun 2011
-
-$1.19 M(+177.4%)
-$1.96 M(+54.4%)
Mar 2011
-
-$427.70 K(+232.6%)
-$1.27 M(-18.1%)
Dec 2010
-$1.55 M(+110.4%)
-$128.60 K(-39.5%)
-$1.55 M(-20.0%)
Sep 2010
-
-$212.40 K(-57.3%)
-$1.93 M(-1.6%)
Jun 2010
-
-$497.40 K(-29.8%)
-$1.96 M(+37.6%)
Mar 2010
-
-$708.30 K(+37.5%)
-$1.43 M(+94.2%)
Dec 2009
-$735.00 K(<-9900.0%)
-$515.10 K(+111.7%)
-$735.00 K(+1308.0%)
Sep 2009
-
-$243.30 K(-719.1%)
-$52.20 K(-215.2%)
Jun 2009
-
$39.30 K(-347.2%)
$45.30 K(-508.1%)
Mar 2009
-
-$15.90 K(-109.5%)
-$11.10 K(<-9900.0%)
Dec 2008
$0.00(-100.0%)
$167.70 K(-215.0%)
$100.00(-100.1%)
Sep 2008
-
-$145.80 K(+752.6%)
-$175.70 K(+312.4%)
Jun 2008
-
-$17.10 K(+263.8%)
-$42.60 K(-26.8%)
Mar 2008
-
-$4700.00(-42.0%)
-$58.20 K(-91.3%)
Dec 2007
-$668.10 K(<-9900.0%)
-$8100.00(-36.2%)
-$668.00 K(+1.2%)
Sep 2007
-
-$12.70 K(-61.2%)
-$659.90 K(+2.0%)
Jun 2007
-
-$32.70 K(-94.7%)
-$647.20 K(+5.3%)
Mar 2007
-
-$614.50 K(-6568.4%)
-$614.50 K(-6568.4%)
Dec 2006
$0.00(-100.0%)
-
-
Dec 2005
$9500.00(>+9900.0%)
$9500.00(>+9900.0%)
$9500.00(>+9900.0%)
Sep 2005
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2005
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2005
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2004
$0.00(0.0%)
$0.00(0.0%)
$0.00(0.0%)
Sep 2004
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2004
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2004
-
$0.00
$0.00
Dec 2003
$0.00
-
-

FAQ

  • What is Sorrento Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Sorrento Therapeutics?
  • What is Sorrento Therapeutics annual CFO year-on-year change?
  • What is Sorrento Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Sorrento Therapeutics?
  • What is Sorrento Therapeutics quarterly CFO year-on-year change?
  • What is Sorrento Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Sorrento Therapeutics?
  • What is Sorrento Therapeutics TTM CFO year-on-year change?

What is Sorrento Therapeutics annual cash flow from operations?

The current annual CFO of SRNE is -$293.86 M

What is the all time high annual CFO for Sorrento Therapeutics?

Sorrento Therapeutics all-time high annual cash flow from operations is $9500.00

What is Sorrento Therapeutics annual CFO year-on-year change?

Over the past year, SRNE annual cash flow from operations has changed by -$12.04 M (-4.27%)

What is Sorrento Therapeutics quarterly cash flow from operations?

The current quarterly CFO of SRNE is -$55.66 M

What is the all time high quarterly CFO for Sorrento Therapeutics?

Sorrento Therapeutics all-time high quarterly cash flow from operations is $1.29 M

What is Sorrento Therapeutics quarterly CFO year-on-year change?

Over the past year, SRNE quarterly cash flow from operations has changed by -$6.20 M (-12.54%)

What is Sorrento Therapeutics TTM cash flow from operations?

The current TTM CFO of SRNE is -$234.63 M

What is the all time high TTM CFO for Sorrento Therapeutics?

Sorrento Therapeutics all-time high TTM cash flow from operations is $45.30 K

What is Sorrento Therapeutics TTM CFO year-on-year change?

Over the past year, SRNE TTM cash flow from operations has changed by +$25.33 M (+9.74%)